Additionally, no significant differences were observed in tumor markers, lymphocyte subsets, cell phenotypes, and their functions when comparing treatments with PD-1 and PD-L1 inhibitors (Supplementary Table 2 and Supplementary Table 3). This evidence concerns the gene PDCD1 and neoplasm.